Diet
GLP-1 Agonists & 'Ozempic Face'
Effective weight loss with a specific facial cost: rapid volume loss ages the midface, and the fat you lose from the face does not come back with the weight.
Also called: ozempic face · semaglutide · skinny jab · tirzepatide
Verdict — mixed
Real in part — the claim outruns what it actually does.
Evidence grade B
At least one good randomised trial, or consistent findings across controlled studies.
Mechanism
GLP-1 receptor agonists reduce appetite and gastric emptying, producing rapid fat loss that includes the deep and superficial facial fat compartments — which contribute far more to a youthful midface than subcutaneous fat elsewhere does.
Citations
- Once-weekly semaglutide in adults with overweight or obesity (STEP 1)New England Journal of Medicine · 2021
- Aging of the facial fat compartments: a volumetric analysisPlastic and Reconstructive Surgery · 2012
The full read
The drugs work; that is not in dispute. The aesthetic trade is real and under-discussed: facial fat compartments are what hold the midface up, and losing them quickly produces temporal hollowing, tear-trough deepening, nasolabial descent and jowling — the 'Ozempic face' look, which reads as five to ten years rather than as leanness. Slower loss, adequate protein and resistance training blunt it. If a GLP-1 is medically indicated, take it and manage the face separately; if the only motivation is facial definition, `leanmaxxing` at a sane rate gets the same jaw without the midface bill.
